Evaluation of the effectiveness of hormone therapy in patients with premature ovarian insufficiency

Titchenko Yu.P.; Kruchinina E.V.; Tikhomirova E.V.; Men’shikova N.S.; Ovchinnikova V.V.; Yarygina T.A.

doi:https://doi.org/10.17116/rosakush20252504186

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4109-0471

Kruchinina E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-3628-0863

Tikhomirova E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-2977-323X

Men’shikova N.S.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4088-6937

Ovchinnikova V.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-6611-2510

Yarygina T.A.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-6140-1930

Evaluation of the effectiveness of hormone therapy in patients with premature ovarian insufficiency

Authors:

Titchenko Yu.P., Kruchinina E.V., Tikhomirova E.V., Men’shikova N.S., Ovchinnikova V.V., Yarygina T.A.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2025;25(4): 86‑93

DOI: 10.17116/rosakush20252504186

Read: 703 times

Contact the author

Table of contents

To cite this article:

Titchenko YuP, Kruchinina EV, Tikhomirova EV, Men’shikova NS, Ovchinnikova VV, Yarygina TA. Evaluation of the effectiveness of hormone therapy in patients with premature ovarian insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2025;25(4):86‑93. (In Russ.)
https://doi.org/10.17116/rosakush20252504186

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

OBJECTIVE

Evaluation of the effectiveness of the effect of various hormone therapy regimens on the severity of clinical symptoms in patients with premature ovarian insufficiency.

MATERIALS AND METHODS

A prospective opened scientific study was conducted involving 56 patients with premature ovarian insufficiency. The general cohort was divided into two groups depending on the reproductive plans of the patients. Group 1 included 31 patients who received hormone replacement therapy aimed to preserve ovarian function with the possible subsequent onset of pregnancy. The 2nd group included 25 patients who had no reproductive plans and were prescribed a combined oral contraceptive. All patients underwent a thorough clinical and laboratory examination, paying attention to the collection of family anamnesis, a clinical assessment of the severity of menopausal syndrome on the Green scale, and the results of hormonal studies. Ultrasound examination of the pelvic organs was performed 2, 6, and 12 months after the start of hormonal therapy. Mathematical methods included statistical analysis carried out using Microsoft Office 2007 and Excel 2007 licensed application programs.

RESULTS

After 12 months of hormone therapy, both groups showed a statistically significant decrease in the severity of such symptoms of estrogen deficiency as sweating and genitourinary menopausal syndrome. In group 2 patients, a statistically significant decrease in the frequency of episodes of insomnia and hot flashes was also achieved. The severity of the remaining symptoms of estrogen deficiency decreased by 2 times when calculated on the Green scale and amounted to 10—11 points, which was regarded as a mild degree of estrogen deficiency. An analysis of the condition of patients in both groups showed that the use of both hormone replacement therapy and a combined oral contraceptive in women with premature ovarian insufficiency helps preserve their physical and mental health and prevent complications associated with estrogen deficiency.

CONCLUSION

Patients with premature ovarian insufficiency need a special approach and therapy depending on their reproductive plans. Early detection of latent and clinically pronounced forms of premature ovarian insufficiency helps the doctor to develop an algorithm for managing patients with this pathology in order to prevent age-related diseases. Patients of both groups showed high compliance and clinical effectiveness of the therapy, which contributes to improving the quality of life.

Keywords:

premature ovarian insufficiency

hormone replacement therapy

menopause

Authors:

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4109-0471

Kruchinina E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-3628-0863

Tikhomirova E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-2977-323X

Men’shikova N.S.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4088-6937

Ovchinnikova V.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-6611-2510

Yarygina T.A.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-6140-1930

Received:

09.08.2024

Accepted:

02.09.2024

Close metadata

References:

Kovalenko LV, Belotserkovtseva LD, Korneeva EV, Shishanok OYu. Early menopause as an independent risk factor for the development of metabolic syndrome Vestnik Rossiiskogo universiteta druzhby narodov. Serya: Meditsina. 2011;1:34-38. (In Russ.).
Azarenkova TA, Vardugina NG. Risk factors for the onset of natural menopause in young women. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8:4:2:25. (In Russ.).
Slopien R, Wender-Ozegowska E, Rogowiez- Frontezak A, Meczekalski B, Zozulinska-Ziolkiewiez D, Jaremek JD. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10.
Adamyan LV, Pivazyan LG. Interdisciplinary approach and the current state of the issue of premature aging of the ovaries (literature review). Russian Journal of Human Reproduction. 2023;29:1:94-103. (In Russ.). https://doi.org/10.17116/repro20232901194
Blinov DV, Khazan PL, Mnatsakan’yan AL, Korabel’nikov DI, Safarov AT, Pavlova NV, Zakharova NS, Ponomarev DA, Petrenko DA. Early menopause and premature ovarian insufficiency: problems and prospects. Akusherstvo, ginekologiya i reproduktsiya. 2020;14:3:328-345. (In Russ.).
Kuh D, Cooper R, Moor A, Richards M, Hardy R. Age at menopause and lifetime cognition Findings from a British birth cohort study. Neurology. 2018;90:19:1673-1681.
Essays on endocrine gynecology. Ed. Radzinskii VE. Moscow: Media Bureau Status Presentation. 2020;576.
Avis NE, Crawford SL, Greendole G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015; 175:4:513-519.
Vorontsova AV, Zvonodny MA, Oboskalova TA, Prokhorova OV. The stage of “counseling” women of perimenopausal age is a necessary condition for optimizing tactics. Ural’skii meditsinskii zhurnal. 2017;6:150:10-17. (In Russ.).
Kuznetsova IV. Menopausal symptoms and sleep disorders in women: the possibilities of alternative therapy. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2019;7:1:85-91. (In Russ.).
Miller VM, Kling JM, Files JA, Joyner MJ, Kapoor E, Moyer AM, Rocca WA, Faubion SS. Whats in a name: are menopausal «hot flashes» a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25:6:700-703.
Chaika KV, Stepanenko TO, Shal’ko MN. Endothelial function and hemostasis system in women with early menopause. Reproduktivnoe zdorov’e. Vostochnaya Evropa. 2019;9:1:38-45. (In Russ.).
Turner RJ, Kerber IJ. A theory of eu- estrogenemia a unifying concept. Menopause. 2017;24:9:1086-1097.
Yureneva SV, Orlova YaA. Menopausal transition is a focus on early and effective reduction of cardiometabolic risks. Doktor.Ru. 2023;22:5:40-48. (In Russ.).
Vinokurova EA, Gorodnicheva IE, Kiseleva MA. The effectiveness of menopausal hormone therapy in women with menstrual syndrome. Gynekologiya. 2020;19:1:38-41. (In Russ.).
Ulumbekova GE, Khudova IYu. Assessment of demographic, social and economic effects when taking menopausal hormone therapy. ORGZDRAV: news, opinions, training. Vestnik VShOUZ. 2020; 6:4:23-53. (In Russ.).
Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Hirschberg AL, Kiesel L, Lopes P, Pines A, van Trotsenburg M, Lambrinoudaki I, Rees M. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020;135:82-88.
Gass MLS, Maki PM, Shifren JL, Schnatz PF, Kaunitz AM, Shapiro M, Sievert LL. NAMS support judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015;22:7:685-686.
Zaidieva Ya.Z. Menopausal hormone therapy and oncological risks of the reproductive system. Literature review. Meditsinskii alfavit. 2019;1-1:376:42-50. (In Russ.).
Oboskalova GA, Koval’ MV. The effect of menopausal hormone therapy on uterine fibroids in postmenopausal women. Ural’skii meditsinskii zhurnal. 2017;6:150:5-9. (In Russ.).
Roehm EA. reappraisal of Womens Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50-59 years of age. Obstet Gynecol Int. 2015;2015:713295.
Balan VE, Tikhomirova EV. Menopausal hormone therapy with minimal risks. Meditsinskii alfavit. 2018;1-6:343:6-9. (In Russ.).
Dubrovina S.O. Rational approach to hormone therapy in women over 40 years of age. Akusherstvo i ginekologiya. 2019;7:112-116. (In Russ.).
Sukhikh GT, Smetnik VP, Andreeva EN, Balan VE, Gavisova AA, Grigoryan OR, Ermakova EI, Zaidieva YaZ, Il’ina LM, Kasyan VN, Marchenko LA, Podzolkova NM, Rogovskaya SI, Smetnik AA, Chernukha GE, Yureneva SV. Menopausal hormone therapy and the preservation of women’s health in adulthood. Russian Journal of Human Reproduction. 2018;24:56:727-756. https://doi.org/10.17116/repro20232902170
Yureneva SV, Dubrovina AV. The advantages of early/timely start of menopausal hormone therapy from the standpoint of the theory of euestrogens. Russian Bulletin of Obstetrician-Gynecologist. 2018;18:5:49-55. (In Russ.). https://doi.org/10.17116/rosakush20181805149
Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: A reappraisal: An Endocrine Socierty clinical practice guideline. J Clin Endocrinol Metab. 2014;99:10:3489-3510.
Baber RJ, Panay N, Fenton A. the IMS Writing Group. 2016 IMS Recommendation on womens midlife and menopause hormone therapy. Climacteric. 2016;19:2:109-150.
Greene Climacteric Scale (GCS). Greene J.G. Constructing a standard climacteric scale. Maturitas. 1998;29:25-31.
Clinical guidelines “Menopause and menopausal state in women”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, 2021. (In Russ.).
Kumykova ZKh, Batyrova ZK, Uvarova EV. Premature ovarian insufficiency in early reproductive age: modern aspects of diagnosis and management. Reproduktivnoe zdorov’e detei i podrostkov. 2019;4:53-60. (In Russ.).
Aleksandrova NV, Gus AI, Marchenko LA, Butareva LB. Echography and Dopplerometry for evaluating the effectiveness of treatment of women with premature ovarian insufficiency. SonoAce International. 2007;16:7-16. (In Russ.).
ESHRE Recommendations «Management of women with premature ovarian insufficiency». 2015;15.
Spiridenko GYu, Petrov YuA, Palieva NV. Reproductive potential of women with premature ovarian insufficiency. Mediko-farmatsevticheskii zhurnal «Pul’s». 2021;23:8:41-48. (In Russ.).